TUSTIN, Calif., April 30 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi, and Jilin, China, is a vertically integrated specialty pharmaceutical company. In combination with its subsidiary Jade Pharmaceutical Inc., (JPI), the Company engages in the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products.
AMDL today announced that JPI has signed a Memorandum of Understanding (MOU) with Zhejiang HuaDu Beauty Co. Ltd. HuaDu owns more than 200 beauty stores and a beauty care training school located in Zhejiang province. The MOU creates a path for HuaDu to sell JPI's Goodnak anti-aging product and a new to-be-launched set of seven new Goodnak non-injectable anti-aging human products. These seven new Goodnak products are anticipated to be marketed during the second and third quarters of 2008.
JPI also recently held a conference in the city of Hangzhou to discuss with various beauty salon operators and regional hospitals the development of JPGREEN Anti-Aging Clinics. These clinics would be developed primarily through the conversion of existing operations into JPGREEN Anti-Aging Clinics locations. It is anticipated that a minimum of 100 JPGREEN Anti-Aging Clinics and at least 13 Hospital operated therapeutic anti-aging clinics would be developed over the next 12 months.
Mr. Gary Dreher, CEO of AMDL, noted that "our new JPGREEN Anti-Aging Clinics concept appears to be the most prudent path to developing and expanding this important area of JPI's business."
About Jade Pharmaceutical: JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, JPI currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements are subject to certain risks and uncertainties, and actual
circumstances, events or results may differ materially from those projected
in such forward-looking statements. The Company cautions readers not to
place undue reliance on any forward-looking statements. The Company does
not undertake, and specifically disclaims any obligation, to update or
revise such statements to reflect new circumstances or unanticipated events
as they occur.
About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.
Contact: AMDL, Inc.
Mr. Paul Knopick
AMDL Investor Relations
Direct Line: 949.707.5365
Voice Mail: 714.505.4460
|SOURCE AMDL, Inc.|
Copyright©2008 PR Newswire.
All rights reserved